GlassScriptPhysician profile
Jeffrey Greenwald
NPI 1679532923
$1,209.49
in general payments reported to CMS, 2019-2025
12 companies · $70.67 in 2025
The $70.67 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2021: $14.48 · 2022: $65.17 · 2023: $99.78 · 2024: $433 · 2025: $70.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $526.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $154.06 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $141.70 | 2023-2024 | Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $91.21 | 2022-2023 | |
| Biofrontera INC. | $66.35 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Biowound Solutions, INC. | $52.85 | 2025 | Bio-Connekt |
| Genzyme Corporation | $46.82 | 2024 | |
| Ucb, INC. | $45.02 | 2024 | Bimzelx |
| Strata Skin Sciences, INC. | $33.19 | 2024 | Xtrac |
| Janssen Biotech, INC. | $19.91 | 2024 | Tremfya |
| Incyte Corporation | $17.82 | 2025 | Opzelura |
| Bausch Health US, LLC | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greenwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.